Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia by Ajnakina, Olesya et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.schres.2018.02.017
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Ajnakina, O., Horsdal, H. T., Lally, J., MacCabe, J. H., Murray, R. M., Gasse, C., & Wimberley, T. (2018).
Validation of an algorithm-based definition of treatment resistance in patients with schizophrenia. Schizophrenia
Research. https://doi.org/10.1016/j.schres.2018.02.017
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
                             Elsevier Editorial System(tm) for 
Schizophrenia Research 
                                  Manuscript Draft 
 
 
Manuscript Number:  
 
Title: Validation of an algorithm-based definition of treatment 
resistance in patients with schizophrenia  
 
Article Type: Short Communication 
 
Keywords: Treatment Resistance, Clozapine, Schizophrenia, Validation, 
Sensitivity, Specificity, Positive Predictive Value, Negative Predictive 
Value 
 
Corresponding Author: Dr. Olesya Ajnakina,  
 
Corresponding Author's Institution:  
 
First Author: Olesya Ajnakina 
 
Order of Authors: Olesya Ajnakina; Henriette Thisted Horsdal ; John 
Lally; James H MacCabe; Robin M Murray ; Christiane  Gasse ; Theresa  
Wimberley  
 
Abstract: Large-scale pharmacoepidemiological research on treatment 
resistance relies on accurate identification of people with treatment-
resistant schizophrenia (TRS) based on data that are retrievable from 
administrative registers. This is usually approached by operationalising 
clinical treatment guidelines by using prescription and hospital 
admission information. We examined the accuracy of an algorithm-based 
definition of TRS based on clozapine prescription and/or meeting 
algorithm-based eligibility criteria for clozapine against a gold 
standard definition using case notes. We additionally validated a 
definition entirely based on clozapine prescription. 139 schizophrenia 
patients aged 18-65 years were followed for a mean of 5 years after first 
presentation to psychiatric services in South-London, UK. The diagnostic 
accuracy of the algorithm-based measure against the gold standard was 
measured with sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV). A total of 45 (32.4%) schizophrenia 
patients met the criteria for the gold standard definition of TRS; 
applying the algorithm-based definition to the same cohort led to 44 
(31.7%) patients fulfilling criteria for TRS with sensitivity, 
specificity, PPV and NPV of 62.2%, 83.0%, 63.6% and 82.1%, respectively. 
The definition based on lifetime clozapine prescription had sensitivity, 
specificity, PPV and NPV of 40.0%, 94.7%, 78.3% and 76.7%, respectively. 
Although a perfect definition of TRS cannot be derived from available 
prescription and hospital registers, these results indicate that 
researchers can confidently use registries to identify individuals with 
TRS for research and clinical practices. 
 
 
 
 
Dr Olesya Ajnakina, PhD 
Department of Psychosis Studies 
Institute of Psychiatry, Psychology 
and Neuroscience 
16 De Crespigny Park, London, 
SE5 8AF  
Email: olesya.ajnakina@kcl.ac.uk 
 
20th November 2017 
 
Dear Professor Matcheri Keshavan,  
Re: Validation of an algorithm-based definition of treatment resistance in patients with 
schizophrenia 
I would be extremely grateful if you could consider the attached manuscript for submission as 
an original short communication for Schizophrenia Research. This manuscript contains original 
work that has not been previously published and has not been submitted for publication elsewhere. 
I can confirm that all authors have contributed significantly to this manuscript, and that all authors 
are in agreement with the contents of the manuscript.  
Large-scale pharmacoepidemiological research on treatment resistance relies on accurate 
identification of people with treatment-resistant schizophrenia (TRS) based on data that are 
retrievable from administrative registers. Some of the authors (J.M., C.G., H.T.H. and T.W.), using 
register data on prescriptions and psychiatric admissions, developed a definition of insufficient 
response, which is based on the clinical guidelines and recommendations, using the data available 
in the Danish prescription and hospital registers. While this definition of TRS has already yielded a 
wealth of insights into treatment-resistant schizophrenia (Wimberley et al., 2016a; Wimberley et al., 
2016b; Wimberley et al., 2017a; Wimberley et al., 2017b; Horsdal et al., 2017), its validity against 
the gold standard definition as based on the NICE guidelines has not been established yet. In this 
study using an independent, well-charaterised and ethnically diverse sample from South-London 
(UK) we examined the accuracy of the algorithm-based definition of TRS based on clozapine 
prescription and/or meeting algorithm-based eligibility criteria for clozapine against the gold 
standard definition in patients with first episode schizophrenia. We additionally validated a 
definition entirely based on clozapine prescription.  
*Cover Letter
The results showed that the algorithm-based definition TRS had a sensitivity, specificity, 
positive predictive value (PPV), and negative predictive value (NPV) of 62.2%, 83.0%, 63.6% and 
82.1%, respectively. The definition based on lifetime clozapine prescription only had sensitivity, 
specificity, PPV and NPV of 40.0%, 94.7%, 78.3% and 76.7%, respectively. We concluded that 
even though a perfect definition of treatment-resistant schizophrenia cannot be derived from 
available prescription and hospital registers, these results indicate that researchers can confidently 
use registries to identify individuals with TRS for research and clinical practices. 
 
Many thanks in advance for your consideration. 
 
Yours sincerely,  
 
Dr Olesya Ajnakina 
Post-Doctoral Researcher 
IoPPN, King’s College London, UK 
 
1 
 
Validation of an algorithm-based definition of treatment resistance in patients with 
schizophrenia 
Olesya Ajnakina a, Henriette Thisted Horsdal b,c, John Lally a, d, e, James H. MacCabe a,f, 
Robin M. Murray a,f, Christiane Gasse b,c, Theresa Wimberley b,c 
 
a Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, 
King’s College London, UK 
b National Centre for Register-based Research, Aarhus BSS, Aarhus University, Aarhus, 
Denmark 
c iPSYCH; the Lundbeck Foundation Initiative for Integrative Psychiatric Research 
d Department of Psychiatry, Royal College of Surgeons in Ireland, Beaumont Hospital, 
Dublin, Ireland 
e Department of Psychiatry, School of Medicine and Medical Sciences, University College 
Dublin, St Vincent's  University Hospital, Dublin, Ireland 
f
 National Institute for Health Research (NIHR) Biomedical Research Centre at South 
London and Maudsley NHS Foundation Trust and King’s College London 
 
* To whom correspondence should be addressed: Dr Olesya Ajnakina, Institute of 
Psychiatry, Psychology & Neuroscience, King’s College London, 16 De Crespigny Park, 
London, SE5 8AF, UK. Tel: +44 (0)20 7848 0518, fax: +44 (0)20 7848 0287, e-mail: 
olesya.ajnakina@kcl.ac.uk. 
*Manuscript
Click here to view linked References
2 
 
Abstract 
Large-scale pharmacoepidemiological research on treatment resistance relies on accurate 
identification of people with treatment-resistant schizophrenia (TRS) based on data that are 
retrievable from administrative registers. This is usually approached by operationalising 
clinical treatment guidelines by using prescription and hospital admission information. We 
examined the accuracy of an algorithm-based definition of TRS based on clozapine 
prescription and/or meeting algorithm-based eligibility criteria for clozapine against a gold 
standard definition using case notes. We additionally validated a definition entirely based on 
clozapine prescription. 139 schizophrenia patients aged 18-65 years were followed for a 
mean of 5 years after first presentation to psychiatric services in South-London, UK. The 
diagnostic accuracy of the algorithm-based measure against the gold standard was 
measured with sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV). A total of 45 (32.4%) schizophrenia patients met the criteria for the gold 
standard definition of TRS; applying the algorithm-based definition to the same cohort led to 
44 (31.7%) patients fulfilling criteria for TRS with sensitivity, specificity, PPV and NPV of 
62.2%, 83.0%, 63.6% and 82.1%, respectively. The definition based on lifetime clozapine 
prescription had sensitivity, specificity, PPV and NPV of 40.0%, 94.7%, 78.3% and 76.7%, 
respectively. Although a perfect definition of TRS cannot be derived from available 
prescription and hospital registers, these results indicate that researchers can confidently 
use registries to identify individuals with TRS for research and clinical practices.  
Key words Treatment Resistance, Clozapine, Schizophrenia, Validation, Sensitivity, 
Specificity, Positive Predictive Value, Negative Predictive Value  
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1. Introduction  
Treatment-resistant schizophrenia (TRS) is a major cause of disability and 
functional impairment worldwide (Kennedy et al., 2014). Approximately 30% of patients 
with schizophrenia will develop TRS at some point during their illness course (Elkis and 
Buckley, 2016; Kane et al., 1988) with all standard treatment guidelines recommending 
these patients be treated with clozapine (National Collaborating Centre for Mental 
Health, 2009; National Institute for Health and Clinical Excellence guideline, 2014). The 
gold standard definition of TRS is generally defined as insufficient response to at least 
two sequential, different antipsychotic medications of adequate doses taken over an 
adequate time period (National Institute for Health and Clinical Excellence guideline, 
2014); though the definition of insufficient response is open to interpretation (Howes et al., 
2016).  
When using register-based data, response, or lack thereof, to antipsychotics often has 
to be inferred from data on service use or changes in prescriptions. This has led researchers 
to design proxy measures of TRS (Huber et al., 2008). Some of the authors (J.M., C.G., 
H.T.H. and T.W.), using register data on prescriptions and psychiatric admissions, 
developed a definition of insufficient response, which is based on the clinical guidelines and 
recommendations, using the data available in the Danish prescription and hospital registers. 
While this definition of TRS has already yielded a wealth of insights into treatment-resistant 
schizophrenia (Wimberley et al., 2016a; Wimberley et al., 2016b; Wimberley et al., 2017a; 
Wimberley et al., 2017b; Horsdal et al., 2017), its validity against the gold standard definition 
has not been established.  
Therefore, we aimed to validate the algorithm-based definition of TRS (Wimberley et 
al., 2016b) compared to the gold standard definition of TRS using the longitudinal data from 
a well-characterised sample of patients with first-episode schizophrenia (FES) collected in 
South-London and who were assessed after first five years of illness (Ajnakina et al., 2017; 
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Lally et al., 2016). Another more simple definition of TRS is based exclusively on lifetime 
clozapine prescription, and has been used in a number of studies (Manuel et al., 2012; 
Wheeler et al., 2014; Wimberley et al., 2016a,b; Horsdal et al., 2017). We additionally 
validated this clozapine definition, which we expect would have close to 100% in positive 
predictive value for detecting TRS patients.  
2. Methods  
2.1. Sample 
Participants were recruited as part of the National Institute of Health Research (NIHR) 
Biomedical Research Centre (BRC) Genetics and Psychosis (GAP) study conducted in 
South-London, UK. Further details of the sample are available in Supplementary Material 
and Di Forti et al., 2014. Among 283 first-episode schizophrenia spectrum psychosis 
patients (International Classification of Diseases (ICD)-10 diagnoses: F20.0, F25.0, F28.0, 
F29.0) (WHO, 1992), 166 were FES patients (ICD-10 diagnoses: F20.0) who formed our 
core analytic sample. Ethical permission was obtained from the South-London and Maudsley 
Mental Health NHS Foundation Trust (SLaM) and the Institute of Psychiatry Research Ethics 
Committee. All patients gave informed written consent after reading a detailed information 
sheet. 
2.2. Tracing patients and data at follow-up  
The patients with FES were traced five years after first contact with mental health 
services (Figure 1). We successfully traced 139 (83.7%) of the original FES cohort, who had 
received adequate trials of antipsychotic medications during the follow-up to ascertain their 
treatment resistant status. Because these data additionally included information on patients 
with first episode of schizophrenia spectrum disorder, we repeated the analyses on the 
extended cohort of 240 patients. Information at follow-up was collated from the electronic 
psychiatric records that are the primary clinical record-keeping system within the SLaM Trust 
(Stewart et al., 2009) using the WHO Life Chart Schedule (LCS) extended version (Morgan 
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et al., 2014; Susser et al., 2000). We used this measure at the end of the follow-up period to 
obtain standardised retrospective assessments of patients’ experiences, clinical and social 
outcomes that were reported by treating clinicians for the entire period of illness. The illness 
period was operationalised as the period from first contact with mental health services to the 
date of the last assessment recorded in electronic notes. The LCS measure has been widely 
used in prospective and retrospective studies (Ajnakina et al., 2017; Schoeler et al., 2017). 
The details of the approach to data extraction are provided in Supplementary Material and 
elsewhere (Ajnakina et al., 2017; Lally et al., 2016). 
Using the LCS extended version we collected detailed information on in-/out-patient 
medication history including the number of antipsychotic medications used prior to 
commencing clozapine, medication initiation/discontinuation dates, antipsychotic dose, and 
the reasons for changing or discontinuing each antipsychotic medication such as lack of 
therapeutic effects, intolerance of antipsychotic medications or self-discontinuation of each 
medication (Lally et al., 2016). We extracted detailed information on reasons for each re-
admission throughout the entire follow-up period, and corresponding admission and 
discharge dates.  
2.3.2. Gold standard definition of TRS 
Following the National Institute for Health and Clinical Excellence (NICE) guideline (NICE 
guideline, 2014), patients were defined as having TRS if during the follow-up period they 
showed little or no symptomatic improvement to at least two consecutive treatments with 
antipsychotic medications of adequate dose and duration (≥6 weeks), as ascertained from 
the clinical records. A non-response to antipsychotic treatment was defined if 1) patients, 
having been treated with an antipsychotic medication of  adequate dose and for an adequate 
duration did not show improvements in their clinical presentation as recorded by treating 
clinicians, and/or 2) the documented reason for switching antipsychotic medication was due 
to a lack of therapeutic response. An adequate daily dose of antipsychotic medication was 
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defined according to a daily dose of ≥400mg chlorpromazine equivalence (Leucht et al., 
2014). We only included as TRS cases those patients who failed to respond and not those 
who were intolerant of antipsychotic medications or those who self-discontinued 
antipsychotic medication.  
2.3.3. Algorithm-based definition of TRS 
The algorithm-based definition of TRS was defined as treatment with clozapine in 
outpatient services and/or meeting the eligibility criterion for clozapine. The eligibility criterion 
entailed psychiatric hospital admission due to schizophrenia during antipsychotic treatment 
(as a proxy for insufficient treatment response) within 18 months after having had two 
outpatient consecutive periods of different treatments with antipsychotic medication for at ≥6 
weeks' duration (Wimberley et al., 2016a,b). Additionally, we used outpatient lifetime 
clozapine prescription to define TRS. 
2.4. Analyses 
The predictive validity of the algorithm-based definition of TRS in determining 
treatment-resistant cases was evaluated with sensitivity, specificity, positive predictive 
values (PPV) and negative predictive values (NPV) (Parikh et al., 2008). All analyses were 
conducted in RStudio version 3.31 (Integrated Development for R. RStudio, Inc., Boston, 
MA). 
3. Results 
3.1. Core analytic cohort 
The core analytic sample comprised 139 FES patients with a mean 5-year follow-up 
(SD=2.5). Of these, 75.9% were male, 31.9% were of white ethnicity, and 46.1% were of 
black ethnicity. Of all patients, 45 (32.4%) met the gold standard definition of TRS. Applying 
the algorithm-based definition of TRS to the same cohort, 44 (31.7%) of patients were 
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defined as TRS during the follow-up period. When applying the clozapine definition the 
proportion of TRS was 16.5% (N=23/139) (Figure 1).  
3.2. Validation of the register-based definition of TRS 
Sensitivity of the algorithm-based definition in determining TRS cases was 62.2%; 
specificity was 83.0%; PPV was moderate (63.6%), and NPV for this definition was high 
(82.1%) (Table 1). Sensitivity and PPV for the clozapine definition compared to the gold 
standard were 40.0% and 78.3%, respectively. These results remained largely unchanged 
when the sample was expanded to schizophrenia spectrum disorders (N=240) (Table 1).  
4. Discussion  
Our results highlight that an algorithm-based definition of TRS, which includes both 
clozapine prescription and an eligibility criterion for clozapine, has a 64% chance of correctly 
identifying TRS cases. Sensitivity of this definition was moderate (62%) and higher than for 
the clozapine definition of TRS (40%). Because clozapine is under-prescribed in clinical 
practices (Howes et al., 2012), the clozapine definition inevitably omits some TRS patients 
leading to the reduced sensitivity. In comparison, the TRS definition that additionally includes 
the eligibility criterion for clozapine is certainly broader in its scope. Still, a readmission could 
have been due to other reasons than insufficient treatment response, such as treatment 
intolerance or non-adherence. Therefore, the sensitivity of this criterion for TRS may be 
improved by encompassing other functional or symptomatic criteria (Lally et al., 2017; Huber 
et al., 2008). Nonetheless, large population-based registers, including the Danish registries, 
tend to lack information on symptoms. Additionally for such registers, data on medications is 
available from outpatient prescriptions only. Not having access to medication histories during 
hospitalisation may have contributed to the moderate sensitivity and positive predictive 
values observed for the algorithm-based definition of TRS; though this is also likely to be due 
to differences in care between the UK and Denmark. Further, the gold standard was based 
on clinical records and not individual/personal assessments for determining TRS. Because 
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we validated two measures including clozapine prescription as a criterion for TRS, the gold 
standard definition of TRS did not include clozapine prescription and might thus not have 
identified all with TRS from other information available in the UK data. However, nearly all 
patients prescribed clozapine are TRS, and in the present study we might thus have 
underestimated the positive predictive values of the algorithm-based definitions of TRS.  
Conclusion 
The extended algorithm-based definition indicative of insufficient treatment response 
to first-line treatment with antipsychotic medications and the clozapine definition should be 
utilised in combination to increase the probability of correctly classifying all true TRS cases.  
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Figure Legends 
Figure 1. Flow chart documenting how patients with first episode schizophrenia were traced 
five years after first contact with mental health services 
 
 
APs, antipsychotic medications  
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Table 1 Sensitivity, specificity, PPV, and NPV of the two algorithm-based definitions of treatment resistance schizophrenia (TRS) comparative 
to the gold standard definition of treatment resistance in patients with schizophrenia and schizophrenia spectrum disorders 
 Definitions of TRS  Sensitivity (%) Specificity (%) PPV (%) NPV (%) 
Schizophrenia (N=139)      
 Algorithm-based TRS (N=44) vs Gold standard 
(N=45)  
 
62.2 83.0 63.6 82.1 
       
 Clozapine (N=23) vs Gold standard (N=45)  40.0 94.7 78.3 76.7 
       
Schizophrenia spectrum disorders (N=240)      
 Algorithm-based TRS (N=68) vs Gold standard 
(N=70)  
 
60.0 84.7 61.7 83.7 
       
 Clozapine (N=32) vs Gold standard (N=43)  38.6 97.1 84.4 79.3 
TRS, treatment resistant schizophrenia; PPV, positive predictive value; NPV, negative predictive value 
Terminology: Algorithm-based - TRS definition combined two criteria for TRS 1) outpatient clozapine prescription; 2) eligible criteria for 
clozapine; Clozapine definition of TRS is solely based on outpatient clozapine prescription as the criterion for TRS. 
Figure(s)
Click here to download high resolution image
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